https://www.selleckchem.com/products/arry-382.html
Copyright ©ERS 2020.BACKGROUND Mepolizumab was available in France as part of an early access programme for patients with severe eosinophilic asthma (nominative Temporary Use Authorisation [nATU]) before its commercialisation. This study aimed to characterise patients who received mepolizumab in the nATU. METHODS This retrospective, observational study analysed data from the hospital medical records of patients up to 24 months after treatment initiation. Study objectives were to describe patient baseline characteristics, the evolution
Aimer
Commentaire
Partagez
